Amazing visualization of talk Harald Schmidt @FORUM Science&Health, July 2019
LET'S CELEBRATE THE PUBLICATION OF TWO HIGH IMPACT PAPERS IN JCI AND PNAS:
Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin Hrabê de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, Harald H.H.W. Schmidt (2019). Journal of Clinical Investigation (JCI) Doi: https://doi.org/10.1172/JCI124283
From single drug targets to synergistic network pharmacology in ischemic stroke
Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. López, Jan Baumbach, Harald H.H.W. Schmidt (2019). Proc. Natl. Acad. Sci. U.S.A (PNAS). Doi: https://doi.org/10.1073/pnas.1820799116
THE 2018 NOBEL PRIZE IN CHEMISTRY FOR PHAGE DISPLAY TECHNOLOGY
Frances Arnold (Pasadena, US) along with Sir Greg Winter (Cambridge, UK) and George Smith (Missouri, US) have been jointly awarded the 2018 Nobel Prize in Chemistry for pioneering work in using Phage Display for the directed evolution of human antibodies, with the aim of producing new pharmaceuticals.
Phage display is a fundamental technology used for antibody-based drug discovery and has resulted in several important innovative therapies for the treatment of cancer, autoimmune and inflammatory diseases, including ramucirumab (Cyramza) for the treatment of advanced gastric cancer and metastatic non-small cell lung cancer, belimumab (Benlysta) for the treatment of systemic lupus, ranibizumab (Lucentis) for neovascular age-related macular degeneration, adalimumab (Humira) for the treatment of rheumatoid arthritis, and more.
Maastricht University is one of the few strongholds of Phage Display Technology in Europe focussing on a different application of antibodies, namely for precision diagnosis of diseases allowing then for more precise therapies. For this Ass. Prof. Dr. Mehmet Kemal Tur was attracted to Maastricht from the Institute of Pathology, Justus-Liebig-University in Giessen, Germany, who has authored than 40 peer-reviewed scientific publications and book chapters in the field of antibody technologies and is co-inventor on six patent applications. Dr. Tur began his scientific career close to Maastricht, as a group leader at the Fraunhofer Institute for Molecular Biology in Aachen, Germany. In 2004, he moved to MorphoSys AG in Munich (Germany). In 2006 he returned to Aachen to the Helmholtz Institute for Biomedical Engineering as group leader “Antibody Engineering”. Dr. Tur now co-leads the diagnostic work package in a European Horizon 2020 project on Systems Medicine and precision diagnostics.
THE KOOTSTRA TALENT FELLOWSHIP 2018/2019
We are very pleased to announce that the Board of the Maastricht UMC+ has honoured the application for the Kootstra Talent Fellowship of our colleague Dr. Ana I. Casas Guijarro in the category talented PhD-students / talented future Post Docs. The Kootstra Talent Fellowship program aims to preserve and stimulate talent for the Maastricht UMC+and to bring together the talent and research group within the Maastricht UMC+. The program is aimed at increasing the chances of future 'personal' grants with external funding, and that can be implemented within the Maastricht UMC+. The Kootstra Talent Fellowship is intended for talented future postdocs.